Quantcast

Latest CD4 Stories

2008-08-05 09:01:31

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a phase 1 clinical trial that has begun enrolling patients. The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A....

2008-07-25 18:00:00

Reducing stress can bolster the immune system in human immunodeficiency virus, or HIV-positive adults, U.S. researchers said. CD4+ T lymphocytes, or CD4 T cells, are the brains of the immune system, coordinating its activity when the body comes under attack. They are also the cells that are attacked by HIV -- the virus slowly eats away at CD4 T cells, weakening the immune system. But the immune systems of HIV/AIDS patients face another enemy as well -- stress, which can accelerate CD4 T...

2008-06-30 09:03:37

RICHMOND, Calif., June 30 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the publication of data demonstrating that human immune system cells (CD4 T-cells) can be made resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)). The data suggest that the ZFN approach, which results in the permanent modification of the CCR5 gene encoding an important receptor for HIV infection, is a promising strategy for the treatment of HIV/AIDS....

2008-06-26 09:03:12

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of data from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, non-lymphoid cancer refractory to standard therapy. The results of this study, performed in collaboration with U.S. National Cancer Institute (NCI) investigators lead by Claude Sportes, Crystal...

2008-06-18 18:00:00

SEATTLE, June 18 /PRNewswire/ -- Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine. Yee and colleagues removed CD4+ T cells, a type of white...

fd84f578b616876682867c27fb83edb51
2008-02-11 14:17:09

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) reported Sunday they have discovered another mechanism used by the AIDS virus to attack cells. More than 33 million people are infected with HIV globally and 25 million have died of AIDS.  Currently, there is no cure or vaccine.  The NIAID team said their findings could open the door to new ways of fighting HIV. The human immunodeficiency virus, or HIV, attacks immune system cells, or lymphocytes, known...

2007-01-12 12:00:20

Pipex Pharmaceuticals, Inc. (OTCBB: PPXP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has completed the previously disclosed planned acquisition of its majority-owned subsidiary, Effective Pharmaceuticals, Inc. (EPI). As a result of this acquisition, Pipex has gained broader control of Effective Pharmaceuticals, Inc.'s (EPI) lead products, Anti-CD4 802-2 and CORRECTA(TM),...

2006-03-28 15:40:00

By Will Boggs, MD NEW YORK (Reuters Health) - Younger age, lack of social support, and complex regimens contribute to poor adherence to antiretroviral therapy among patients with HIV infection. Adherence to antiretroviral drug regimens is important and treatment needs to be closely monitored for indications of disease progression, such as an increase in viral load and a decrease in CD4 cell levels, Dr. Sabina De Geest from University of Basel, Switzerland told Reuters Health. De Geest and...

2006-03-23 13:54:06

NEW YORK (Reuters Health) - Behavioral problems and lower than average scores on tests measuring development and intellectual capacity are common in HIV-infected children, according to a report in the journal Pediatrics. HIV-infected children are at high risk for developing neurological and neurodevelopmental impairments, the authors explain, but the effect of HIV infection on specific behavioral issues is poorly understood. Dr. Molly L. Nozyce from the Bronx Lebanon Hospital Center,...

2006-02-07 15:33:52

By Maggie Fox, Health and Science Correspondent DENVER (Reuters) - When it comes to fighting the AIDS virus, the sooner patients start taking powerful drug cocktails, the better -- even when it comes to side-effects known as toxicities, U.S. researchers reported on Tuesday. Deaths, the rate of opportunistic infections and side effects all were the lowest in patients who started treatment early -- while their immune systems were still relatively intact, the team at the University of...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related